ObsEva (NASDAQ:OBSV) & ProMetic Life Sciences (OTCMKTS:PFSCF) Critical Comparison

Institutional and Insider Ownership

0.1% of ProMetic Life Sciences shares are owned by institutional investors. Comparatively, 17.5% of ObsEva shares are owned by institutional investors. 14.4% of ObsEva shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk & Volatility

ProMetic Life Sciences has a beta of 2.46, meaning that its stock price is 146% more volatile than the S&P 500. Comparatively, ObsEva has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500.

Profitability

This table compares ProMetic Life Sciences and ObsEva’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProMetic Life Sciences	-894.02%	-3,350.55%	-67.76%
ObsEva	N/A	-416.36%	-92.01%

Valuation & Earnings

This table compares ProMetic Life Sciences and ObsEva”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProMetic Life Sciences	$36.55 million	3.49	-$150.73 million	N/A	N/A
ObsEva	N/A	N/A	-$58.38 million	($0.92)	N/A

ObsEva has lower revenue, but higher earnings than ProMetic Life Sciences.

Summary

ObsEva beats ProMetic Life Sciences on 5 of the 8 factors compared between the two stocks.

About ProMetic Life Sciences

Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.

About ObsEva

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.